Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (\>18 years old)~* Early-stage breast cancer patients who will receive adjuvant paclitaxel~* Performance status according to Eastern Cooperative oncology group (ECOG) \< 2.~* Adequate bone marrow function (white blood count ≥4,000/mm3, platelet count ≥100,000/mm3), liver function (serum total bilirubin \<1.5 mg/dl), renal function (creatinine\<1.5 mg/dl).~Exclusion Criteria:~* Clinical neuropathy at prior to enrollment.~* Patients treated with medications that increase the risk of neuropathy like amiodarone, Colchicine, metronidazole, phenytoin.~* Patients with a history of hypersensitivity to metformin.~* Pregnant or lactating females.~* Patients who are using metformin for any other cause.~* Patients with Diabetes mellitus.~* Receiving vitamin B1, B6, B12 or another vitamin supplemental therapy.~* Receiving antidepressants, opioids, adjuvant analgesic agents (eg, anticonvulsants, clonazepam, or mexiletine), topical analgesics, and amifostine.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Group I (metformin group) (Type: EXPERIMENTAL): who will receive adjuvant paclitaxel in addition to metformin tablets (1700 mg daily) during the chemotherapy treatment duration.
- Group II (control group) (Type: PLACEBO_COMPARATOR): who will receive adjuvant weekly paclitaxel.

Based on this trial design, predict the completion outcome and termination type (if applicable).